LifeTech Scientific (HKG:1302) said its heart implant was admitted into China's fast-track approval pathway, according to a Hong Kong bourse filing Friday.
The device -- a congenital heart defect occluder designed to treat patent ductus arteriosus -- was accepted into a National Medical Products Administration program for innovative medical devices.
The inclusion is expected to shorten the registration process and speed up the product's launch, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.